These are tough times for contract sales organizations (CSOs). A slowdown in new drug approvals, combined with the creation of super-sized sales forces via drug industry consolidation, mean drug companies are less likely to augment their own sales capabilities. Moreover, the fortunes of CSOs are inextricably linked with those of its troubled pharmaceutical clients. Even in the US, which remains the most profitable market, the dominant CSOs—inVentiv Health Inc. ; Innovex (a unit of Quintiles Transnational Holdings Inc. ) and PDI Inc. —are all struggling.
The problems facing CSOs are particularly acute in Europe. Though the key international players, Ventiv and Innovex, have US-based parents,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?